{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:03:55Z","timestamp":1760781835958},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":14613,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1976,1]]},"abstract":"<jats:p>The effect of oral vitamin D<jats:sub>3<\/jats:sub> therapy on calcium balance was compared in 18 institutionalized subjects with drug\u2010induced osteomalacia and in 18 similar subjects without osteomalacia. The subjects with osteomalacia were receiving standard doses of phenytoin and phenobarbital. Diagnosis of osteomalacia was based on low serum calcium and phosphorus, elevated alkaline phosphatase, and appropriate roentgenographic bone changes. The study group achieved positive calcium balance at approximately 975 IU of vitamin D<jats:sub>3<\/jats:sub> per day, while the control group achieved positive calcium balance at approximately 380 IU of vitamin D<jats:sub>3<\/jats:sub> per day. The difference is highly significant (p &lt; 0.001). These data support previous observations that the osteomalacia of patients receiving anticonvulsant drugs is related to the drugs and that these patients require supplemental doses of vitamin D.<\/jats:p>","DOI":"10.1002\/cpt197619163","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:38:37Z","timestamp":1451957917000},"page":"63-67","source":"Crossref","is-referenced-by-count":18,"title":["Calcium balance in drug\u2010induced osteomalacia: Response to vitamin D"],"prefix":"10.1111","volume":"19","author":[{"given":"Patti","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith G.","family":"Tolman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt197619163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt197619163","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt197619163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:31:07Z","timestamp":1699363867000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt197619163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1976,1]]}},"alternative-id":["10.1002\/cpt197619163"],"URL":"https:\/\/doi.org\/10.1002\/cpt197619163","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1976,1]]}}}